[Skip to Content]
[Skip to Content Landing]
Article
January 1992

Evidence for Interference With the Intestinal Absorption of Levothyroxine Sodium by Aluminum Hydroxide

Author Affiliations

From the Institute of Gastroenterology (Dr Sperber) and the Endocrinology Service (Dr Liel), Division of Internal Medicine, Soroka Medical Center and the Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel. Dr Sperber is currently at the School of Public Health, University of North Carolina at Chapel Hill.

Arch Intern Med. 1992;152(1):183-184. doi:10.1001/archinte.1992.00400130181024
Abstract

A patient with hypothyroidism who was euthyroid on a fixed-dosage, long-term maintenance regimen of levothyroxine sodium developed persistently elevated serum thyrotropin levels while receiving an aluminum hydroxide— containing antacid. The thyrotropin levels returned to normal shortly after cessation of the antacid therapy. These observations indicate that aluminum hydroxide may interfere with the bioavailability of thyroxine. The thyroid function of patients who are receiving replacement or suppressive thyroxine therapy should be monitored following the commencement of concurrent treatment with medications containing aluminum hydroxide.

(Arch Intern Med. 1992;152:183-184)

References
1.
Read DG, Hays MT, Hershman JM.  Absorption of oral thyroxine in hypothyroid and normal men . J Clin Endocrinol Metab. 1970;30:798-799.Article
2.
Hays MT.  Thyroid hormone and the gut . Endocrine Res. 1988;14:203-224.Article
3.
Mayant NB.  Biliary excretion of thyroxine in humans . Clin Sci. 1956;15:227-237.
4.
Mayant NB.  Enterohepatic circulation of thyroxine in humans . Clin Sci. 1956;15:551-555.
5.
Northcutt RC, Stiel JN, Hollinfield JW, et al.  The influence of cholestyramine on thyroxine absorption . JAMA. 1969;208:1857.Article
6.
Faber J, Lumholtz IB, Kirkegaard C, et al.  The effects of phenytoin (diphenylhydantoin) on the extrathyroidal turn-over of thyroxine 3,5,3′-triiodothyronine, 3,3′,5′-triiodothyronine and 3′,5′-diiodothyronine in man . J Clin Endocrinol Metab. 1985;61:1093-1099.Article
7.
Lumholtz IB, Siersbaek-Nielsen K, Faber J, Kirkegaard C, Friis T.  Effect of propranolol on extrathyroidal metabolism of thyroxine and 3,3′,5-triiodothyronine evaluated by noncompartmental kinetics . J Clin Endocrinol Metab. 1978;47:587-589.Article
8.
Bergman F, Halvorsen P, Van der Linden W.  Increased excretion of thyroxine by feeding activated charcoal to Syrian hamsters . Acta Endocrinol. 1967;56:521-524.
9.
American Medical Association, Department of Drugs. Drug Evaluation . Philadelphia, Pa: WB Saunders Co; 1990.
10.
Brunton LL.  Agents for control of gastric acidity and treatment of peptic ulcer . In: Gilman AG, Rall TW, Nies AS, Taylor P, eds. The Pharmacological Basis of Therapeutics. 8th ed. Elmsford, NY: Pergamon Press Inc; 1985:897-913.
11.
Cousar GD, Gasdacz TR.  Comparison of antacids on the binding of bile salts . Arch Surg. 1984;119:1018-1020.Article
12.
Kivilaakso EA.  Antacids and bile salts . Scand J Gastroenterol. 1982;17( (suppl) ):16-19.
13.
Thompson WO, Thompson PK, Dickie LFN, et al.  Effect of alkali on the absorption of thyroxine from the gastrointestinal tract . Arch Intern Med. 1933;52:809-820.Article
14.
Sperber AD, Zuili I, Bearman JE, Shany S.  The effect of an antacid-containing aluminum hydroxide on plasma cholesterol and lipoproteins . Curr Ther Res. 1988;44:426-433.
15.
Utiger RD.  The thyroid: physiology, hyperthyroidism, hypothyroidism, and the painful thyroid . In: Felig P, Broadus AE, Frohman LA, eds. Endocrinology and Metabolism . 2nd ed. New York, NY: McGraw-Hill International Book Co; 1987: chap 10.
×